Journal of Pharmacokinetics & Experimental Therapeutics
Open Access

Infliximab is a monoclonal antibody used for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. As a tumor necrosis factor-alpha (TNF-α) inhibitor, infliximab targets and neutralizes TNF-α, a key pro-inflammatory cytokine involved in the pathogenesis of these conditions. By inhibiting TNF-α, infliximab reduces inflammation, alleviates symptoms, and prevents tissue damage in patients with autoimmune disorders. Given its widespread use and complex pharmacokinetic properties, understanding the pharmacokinetics of infliximab is crucial for optimizing its therapeutic application, ensuring efficacy, and minimizing adverse effects. Pharmacokinetics refers to the study of a drug’s absorption, distribution, metabolism, and elimination (ADME) within the body. Infliximab, as a biologic drug, has distinct pharmacokinetic characteristics compared to small-molecule drugs. Unlike conventional oral medications, infliximab is administered intravenously (IV), ensuring complete bioavailability [1]. This route of administration bypasses gastrointestinal absorption and first-pass metabolism, allowing for more predictable and effective drug delivery.

Methodology

The pharmacokinetics of Infliximab, a monoclonal antibody used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis, involves its absorption, distribution, metabolism, and excretion (ADME). Understanding these processes is crucial for optimizing dosing schedules and minimizing side effects.

Absorption of infliximab

Unlike many traditional small-molecule drugs, infliximab is administered intravenously (IV), which ensures complete bioavailability. The drug is delivered directly into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism. This intravenous administration is crucial because it ensures that the therapeutic concentration of infliximab reaches its target the TNF-α molecules without any loss of drug in the absorption process, as would be the case with oral formulations [2].

Following IV infusion, infliximab is rapidly distributed into the body, and plasma concentrations peak at the end of the infusion. The rate of infusion and the total dose of the drug influence the concentration-time profile. Infliximab is typically administered in a clinical setting, often with initial loading doses followed by maintenance doses, depending on the disease and patient characteristics. A standard regimen for rheumatoid arthritis, for example, consists of loading doses at 0, 2, and 6 weeks, followed by maintenance doses every 8 weeks thereafter.

Distribution of infliximab

Once in the bloodstream, infliximab exhibits a large volume of distribution (Vd), which is characteristic of biologic drugs. The drug distributes extensively into the extracellular fluid, where it targets TNF-α present in the inflammatory tissues, particularly at the site of inflammation. Infliximab’s distribution is heavily influenced by factors such as its molecular size and its affinity for the TNF-α target [3].

As a large molecule (approximately 150 kDa), infliximab is restricted in its ability to cross the blood-brain barrier and is unlikely to reach the central nervous system in therapeutic concentrations. However, the drug does accumulate in inflamed tissues, such as the synovium in rheumatoid arthritis or the mucosa in Crohn’s disease, where it exerts its anti-inflammatory effects.

Infliximab binds to TNF-α with high specificity and affinity, neutralizing its activity and reducing the downstream inflammatory cascade. By inhibiting TNF-α, infliximab reduces inflammation, pain, and damage to tissues affected by autoimmune disorders.

Metabolism of infliximab

The metabolism of infliximab is primarily mediated by proteolytic degradation rather than through traditional hepatic or renal clearance pathways that are seen with small-molecule drugs. Once infliximab binds to TNF-α, the complex is internalized by cells and subsequently degraded by intracellular proteases [4]. Infliximab itself does not undergo significant metabolic transformation in the liver, and the breakdown products are eventually excreted via the reticuloendothelial system (RES), primarily through macrophages and other immune cells.

The half-life of infliximab is relatively long, ranging from 7 to 12 days in most patients, which allows for infrequent dosing regimens once a maintenance dose is established. This extended half-life is a result of its large molecular size and high affinity for TNF-α, which ensures its prolonged presence in the body and maximizes its therapeutic effect [5]. The half-life may be prolonged in patients with higher serum concentrations or those who are responding well to treatment.

Infliximab’s pharmacokinetic profile can vary based on several patient-related factors. Antidrug antibodies (ADAs) are one of the most significant variables affecting the metabolism and efficacy of infliximab. The presence of ADAs can neutralize the drug, reducing its efficacy and potentially accelerating its clearance from the body. Patients with high ADA titers often require more frequent dosing or dose adjustments to maintain therapeutic effectiveness.

Elimination of infliximab

The elimination of infliximab is primarily through proteolytic catabolism and not through the typical renal or hepatic clearance mechanisms seen in smaller molecules. Infliximab’s large molecular size means it is not filtered by the kidneys but is rather processed and degraded by immune cells. The drug is slowly cleared from the bloodstream, and its elimination rate depends on factors like the dose, frequency of infusion, and individual patient characteristics.

Patients with autoimmune diseases often show different rates of elimination. Inflammatory cytokine levels, the presence of ADAs, and the degree of immune response all play a role in the drug's clearance from the body [6]. In general, patients who develop antibodies against infliximab tend to have higher clearance rates, meaning they may require higher or more frequent doses to achieve therapeutic levels.

Factors affecting infliximab pharmacokinetics

Several factors can influence the pharmacokinetics of infliximab, leading to variability in drug concentrations and clinical outcomes. Key factors include:

Disease characteristics: Active inflammation in diseases like rheumatoid arthritis or Crohn's disease may alter the pharmacokinetics of infliximab, potentially leading to faster drug clearance in inflamed tissues. In contrast, patients in remission may experience slower clearance rates [7, 8].

Immune system function: The development of antidrug antibodies (ADAs) against infliximab can lead to accelerated drug clearance, reduced drug efficacy, and the risk of infusion reactions. The presence of ADAs necessitates dose adjustments or switching to alternative biologics.

Body weight: Larger patients may require higher doses to achieve similar drug concentrations to those of smaller patients. Weight-based dosing regimens are sometimes used to adjust for this factor [9, 10].

Concomitant medications: Certain drugs, especially those that affect the immune system (e.g., methotrexate), may alter the pharmacokinetics of infliximab by affecting immune responses or drug clearance.

Conclusion

Infliximab is a highly effective biologic therapy used to treat a variety of autoimmune and inflammatory diseases. Its pharmacokinetics—characterized by intravenous administration, extensive distribution, slow elimination, and susceptibility to immune system interactions—play a crucial role in determining its therapeutic efficacy and safety profile. Understanding these pharmacokinetic properties allows for personalized treatment strategies that optimize dosing regimens, minimize side effects, and enhance overall patient outcomes. Regular monitoring of serum drug concentrations and antidrug antibodies is critical to ensuring that infliximab remains an effective and safe treatment for patients with chronic inflammatory conditions.

1. Zhang HF, Li ZH, Liu JY, Liu TT, Wang P, et al. (2016) Correlation of cytochrome P450 oxidoreductase expression with the expression of 10 isoforms of cytochrome P450 in human liver. Drug Metab Dispos 44:1193-1200.

Indexed at, Google Scholar, Crossref

2. Puymirat E, Lamhaut L, Bonnet N, Aissaoui N, Henry P, et al. (2016) Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French registry of acute ST-elevation and non-ST-elevation myocardial infarction) programmm. Eur Heart J 37:1063-1071.

Indexed at, Google Scholar, Crossref

3. Alam P , Chaturvedi SK, Siddiqi MK, Rajpoot RK, Ajmal MR, et al. (2016) Vitamin k3 inhibits protein aggregation: implication in the treatment of amyloid diseases. Sci Rep 6:26759.

Indexed at, Google Scholar, Crossref

4. Mazerska Z, Mróz A, Pawlowska M, Augustin E (2016) The role of glucuronidation in drug resistance. Pharmacol Ther 159:35-55.

Indexed at, Google Scholar, Crossref

5. Qi C, Fu J, Zhao H, Xing H, Dong D, et al. (2019) Identification of UGTs and BCRP as potential pharmacokinetic determinants of the natural flavonoid alpinetin. Xenobiotica 49:276-283.

Indexed at, Google Scholar, Crossref

6. Pettersson Bergstrand M, Richter LH, Maurer HH, Wagmann L, Meyer MR (2019) In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases. Drug Test Anal 11:45-50.

Indexed at, Google Scholar, Crossref

7. Chen X, Zhang Q, Cheng Q, Ding F (2009) Protective effect of salidroside against H2O2-induced cell apoptosis in primary culture of rat hippocampal neurons. Mol Cell Biochem 332:85-93.

Indexed at, Google Scholar, Crossref

8. Fountain NB, Krauss G, Isojarvi J, Dilley D, Doty P, et al. (2013) Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures. Epilepsia 54:58-65.

Indexed at, Google Scholar, Crossref

9. Cawello W, Boekens H, Bonn R (2012) Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration. Eur J Drug Metab Pharmacokinet 37:241-8.

Indexed at, Google Scholar, Crossref

10. Chen W, Chan Y, Wan W, Li Y, Zhang C et al. (2018) Aβ1-42 induces cell damage via RAGE-dependent endoplasmic reticulum stress in bEnd 3 cells. Exp Cell Res 362:83-89.

Indexed at, Google Scholar, Crossref